# US 8,278,327 B2 · PDE10 inhibitors and related compositions and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,327 B2
- Document ID: US8278327B2
- Status: Granted
- Kind: B2
- Application number: 12/848,766
- Filed: 2010-08-02
- Published: 2011-01-27
- Granted: 2012-10-02
- Earliest claimed: 2006-11-26
- Assignees: Omeros Corporation
- Inventors: John E. Bergmann; Neil S. Cutshall; Rene Onrust; Hongkui Zeng; Jennifer Lynn Gage; Derek Johnston; Sándor Cseh; László Ürögdi; Ákos Papp
- Web page: https://patentgrep.com/patent/US8278327B2

## CPC

- A61K 31/341: not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/4409: only substituted in position 4, e.g. isoniazid, iproniazid
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/4965: Non-condensed pyrazines
- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61P 25/00: Drugs for disorders of the nervous system
- C07D 209/18: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 213/81: Amides; Imides
- C07D 215/36: Sulfur atoms (C07D215/24 takes precedence)
- C07D 235/16: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 235/28: Sulfur atoms
- C07D 249/18: Benzotriazoles
- C07D 279/16: condensed with one six-membered ring
- C07D 333/24: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. The compounds have the general structure: wherein m, n, p, x, R, R1, R2, R3, R4, R5, A and B, are defined herein, including pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same.

## Claims

### Claim 1

A method for treating schizophrenia or psychosis in a warm-blooded animal in need thereof, comprising administering to the animal an effective amount of a compound having the following structure (I):
or a pharmaceutically acceptable salt or stereoisomer thereof,
wherein:
m, n and p are individually 0 or 1;
x is 1, 2 or 3;
A is an optionally substituted heterocycle, wherein the heterocycle is quinoline;
B is —O—, —NR6— or —S(O)z— where z is 0, 1 or 2;
R is hydrogen or oxo;
R1 is absent or represents 1, 2 or 3 substituents that are the same or different and independently halogen, C1-6alkyl, —CHF2, —CF3, —CH2NH2, —CH2NH(C1-6alkyl) or —CH2N(C1-6alkyl)2;
R2 is at each occurrence the same or different and independently, hydrogen, C1-6alkyl, —C(═O)(C1-6alkyl), benzyl, —CH2CONH2, —CHF2, —or —CF3—; and
R3, R4, R5 and R6 are the same or different and independently hydrogen or C1-6alkyl.

### Claim 2 (depends on 1)

The method of claim 1 wherein the compound has the following structure (II):

### Claim 3 (depends on 1)

The method of claim 1 wherein the compound has the following structure (III):

### Claim 4 (depends on 1)

The method of claim 1 wherein the compound has the following structure (IV):

### Claim 5 (depends on 1)

The method of claim 1 wherein the compound has the following structure (V):

### Claim 6 (depends on 1)

The method of claim 1 wherein the compound has the following structure (VI):

### Claim 7 (depends on 1)

The method of claim 1 wherein the compound has the following structure (IVa):

### Claim 8 (depends on 7)

The method of claim 7 wherein:
A is
x is 3 and the —OR2 groups are located at the 3, 4 and 5 positions;
R1 is absent;
R2 is at each occurrence the same or different and independently hydrogen, C1-6alkyl, —C(═O)(C1-6alkyl), benzyl, —CH2CONH2, —CHF2 or —CF3; and
R3, R4 and R5 are hydrogen.

### Claim 9 (depends on 8)

The method of claim 8 wherein R2 is at each occurrence the same or different and independently, C1-6alkyl or —CHF2 or —CF3.

### Claim 10 (depends on 7)

The method of claim 7 wherein:
A is
x is 2 or 3 and two of the —OR2 groups are located at the 3 and 4 positions;
R1 is absent;
R2 is at each occurrence the same or different and independently C1-6alkyl, —CHF2 or —CF3;
R3, R4 and R5 are hydrogen; and
R7 is —O(C1-6alkyl).

### Claim 11 (depends on 1)

The method of claim 1 wherein the compound has the following structure (IVb):

### Claim 12 (depends on 1)

The method of claim 1 wherein the compound has the following structure (IVc):

### Claim 13 (depends on 1)

The method of claim 1 wherein the compound has the following structure (IVg):
wherein:
a is 1, 2, 3 or 4;
b is 0.1 or 2; and
R7 and R8 are the same or different and independently hydrogen, halogen, C1-6alkyl, —O(C1-6alkyl), C1-6haloalkyl or nitro.

### Claim 14 (depends on 13)

The method of claim 13 wherein:
x is 1,2 or 3;
a is 1;
b is 0;
R1 is absent or represents 1, 2, or 3 substituents that are the same or different and independently halogen, C1-6alkyl, —CHF2, —CF3, —CH2NH2, —CH2NH(C1-6alkyl) or —CH2N(C1-6alkyl)2;
R2 is at each occurrence the same or different and independently hydrogen, C1-6alkyl, —C(═O)(C1-6alkyl), benzyl, —CH2CONH2, —CHF2 or —CF3;
R3, R4 and R5 are hydrogen; and
R7 is halogen or C1-6haloalkyl.

### Claim 15 (depends on 14)

The method of claim 14 wherein R2 is at each occurrence the same or different and independently C1-6alkyl, —CHF2 or —CF3.

### Claim 16 (depends on 14)

The method of claim 14 wherein R1 is absent or represents 1, 2, or 3 substituents that are the same or different and independently halogen, C1-6alkyl, —CHF2 or —CF3.
